最近,血清支链氨基酸(BCAAs)水平已被认为是评估健康状况和预测慢性病风险的指标。本系统评价和荟萃分析旨在评估血清BCAAs与全因死亡风险之间的关系。我们对各种重要数据库进行了全面系统的检索,包括PubMed,Scopus,和WebofScience数据库查找截至2022年10月发表的相关研究,没有语言,设计,或时间限制。我们在队列和病例对照研究中提取了95%置信区间(CI)的报告风险比(HR)和95%CI的比值比(OR)。分别,并计算对数HR或OR及其标准误差。然后,我们使用随机效应模型与方差反加权方法进行了本荟萃分析,来计算合并效应的大小。十项观察性研究,包括9项队列研究和1项病例对照研究,被纳入本荟萃分析。参与者人数从53到26,711不等,年龄范围为18-99岁。在6个月至24年的随访期间,已确定3599人死亡。汇总结果表明,血清BCAAs之间没有显着关联(RR:1.17;95%CI0.85-1.60),异亮氨酸(RR:1.41;95CI0.92-2.17),亮氨酸(RR:1.13;95%CI0.94-1.36),和缬氨酸(RR:1.02;95CI0.86-1.22)和全因死亡率。此外,血清BCAAs研究之间存在显着异质性(I2=74.1%,P异质性=0.021),异亮氨酸(I2=89.4%,P异质性<0.001),亮氨酸(I2=87.8%,P异质性<0.001),和缬氨酸(I2=86.6%,P异质性<0.001)。我们的结果表明,血清BCAAs及其成分,包括异亮氨酸,亮氨酸,和缬氨酸,与全因死亡风险无关.
Recently, the serum levels of branched-chain amino acids (BCAAs) have been considered as an indicator to evaluate health status and predict chronic diseases risk. This systematic review and meta-analysis aimed to assess the relationship between Serum BCAAs and the risk of all-cause mortality. We carried out a comprehensive and systematic search in various important databases, including PubMed, Scopus, and Web of Science databases to find the relevant studies published up to October 2022 with no language, design, or time limitation. We extracted the reported hazard ratio (HR) with 95% confidence interval (CI) and odds ratio (OR) with 95%CI in cohorts and case-control studies, respectively, and computed the log HR or OR and its standard error. Then, we used the random-effects model with inverse variance weighting method for the present meta-analysis, to calculate the pooled effect size. Ten observational studies, including nine cohort studies and one case-control study, were included in the present meta-analysis. The number of participants ranges from 53 to 26,711, with an age range of 18-99 years. During 6 months to 24 years of follow-up, 3599 deaths were ascertained. The pooled results indicated that there was no significant association between serum BCAAs (RR: 1.17; 95% CI 0.85-1.60), isoleucine (RR: 1.41; 95%CI 0.92-2.17), leucine (RR: 1.13; 95% CI 0.94-1.36), and valine (RR: 1.02; 95%CI 0.86-1.22) and all-cause mortality. Also, there was significant heterogeneity between studies for serum BCAAs (I2 = 74.1% and P-heterogeneity = 0.021), isoleucine (I2 = 89.4% and P-heterogeneity < 0.001), leucine (I2 = 87.8% and P-heterogeneity < 0.001), and valine (I2 = 86.6% and P-heterogeneity < 0.001). Our results suggested that the serum BCAAs and its components, including isoleucine, leucine, and valine, were not associated with the risk of all-cause mortality.